让我们发挥作用：药物敏感性分析以实现精准肉瘤医学。

Let's get functional: Drug sensitivity profiling to enable precision sarcoma medicine.

机构信息

Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT), NCT/University Cancer Center Dresden, a partnership between German Cancer Research Center (DKFZ), Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology (TUD), and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology (TUD), Dresden, Germany; Faculty of Biology, Dresden University of Technology (TUD), Dresden, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.

Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany; Division of Translational Precision Medicine, Institute of Human Genetics, Heidelberg University, Heidelberg, Germany.

出版信息

Cell Stem Cell. 2024 Oct 3;31(10):1389-1390. doi: 10.1016/j.stem.2024.09.006.

DOI:10.1016/j.stem.2024.09.006

PMID:39366358

Abstract

Drug sensitivity profiling in patient-derived tumor models offers new hope for improving outcomes in cancers lacking effective therapies. Al Shihabi et al. demonstrate that short-term cultures from bone and soft tissue sarcomas enable clinically meaningful screening of multiple drugs and combinations, marking a significant advance in personalized care for these high-risk diseases.

摘要

在缺乏有效治疗方法的癌症中，患者来源肿瘤模型的药物敏感性分析为改善治疗效果带来了新的希望。Al Shihabi 等人证明，骨和软组织肉瘤的短期培养能够对多种药物和组合进行有临床意义的筛选，这标志着这些高危疾病的个性化治疗取得了重大进展。